Topic: How To Invest

Power Growth Investor Hotline – Friday, April 25, 2025

Article Excerpt

ELI LILLY AND COMPANY, $884.54, is a buy. The drugmaker (symbol LLY on New York) discovers, develops, manufactures and markets human pharmaceutical products. Lilly’s shares took a big jump recently after the company said its experimental diabetes/weight loss pill met its goals in a pivotal Phase 3 study, helping diabetes patients lower blood sugar—and even reduce weight. The results are the first from several studies of the daily pill, called orforglipron, expected this year from Lilly in patients with Type 2 diabetes and obesity. This brings an oral version of the booming class of drugs closer to patients aiming to lose weight. Doctors and patients have been hoping for pill versions of popular GLP-1s for weight loss. All approved versions so far are given by injection, and a pill would be a more convenient option. Many patients are hesitant to use an injectable, which also require refrigeration when they are stored or transported; and the pill potentially opens up the market to parts…